NewcelX AG, formerly NLS Pharmaceutics AG, is a Switzerland-based company primarily engaged in the biotechnology industry. The Company focuses on the discovery and development of therapies for rare and complex central nervous system (CNS) disorders, including sleep and neurodevelopmental conditions. The Company offers products like Quilience, which is a clinical-stage pharmaceutical compound. It aims to support the treatment of narcolepsy by modulating monoamine neurotransmission and orexin receptor activity. The Company also develops product like Nolazol, a treatment candidate for Attention Deficit Hyperactivity Disorder (ADHD). The Company is a publicly traded company, listing on the NASDAQ.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	5.34Cr 1.78Cr 1.54Cr 1.44Cr 1.32Cr 2.48Cr 169.6Cr 2.52Cr 17Cr 6.63Cr 85Cr 6.69Cr 6.55Cr 281.03Cr	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	5.34Cr 1.78Cr 1.54Cr 1.44Cr 1.32Cr 2.48Cr 169.6Cr 2.52Cr 17Cr 6.63Cr 85Cr 6.69Cr 6.55Cr 281.03Cr	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	33.95%	Yield 2026 *	-	Yield 2027 *	-

31/07	NewcelX Ltd. announced that it expects to receive $1.399991 million in funding	CI
15/07	NewcelX Obtains Patent in Brazil for Potential Type 1 Diabetes Treatment	MT
08/07	Newcelx Ltd. Announces Appointment of Camillo Ricordi to Scientific Advisory Board	CI
01/07	NewcelX Ltd. Announces Successful FDA Pre-IND Meeting With Clear Path Forward For NCEL-101 Toward Starting Clinical Trials For Type 1 Diabetes	CI
15/06	NewcelX Publishes Peer-Reviewed Study Demonstrating Broad Therapeutic Potential Of Its Stem Cell Technology Platform	CI
27/05	Newcelx submits pre-IND package to FDA for NCEL-101 for treatment of type 1 diabetes	RE
27/05	NewcelX Submits Pre-IND Package To FDA For NCEL-101 For The Treatment Of Type 1 Diabetes	CI
30/04	NewcelX Ltd. announced that it has received $1.349994 million in funding	CI
30/04	NewcelX Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
29/04	NewcelX Ltd. Auditor Raises 'Going Concern' Doubt	CI
20/04	Newcelx updates corporate presentation to highlight type 1 diabetes flagship program	RE
02/04	NewcelX Ltd. announced that it expects to receive $1.349994 million in funding	CI
09/03	NewcelX announces strategic collaboration with Eledon Pharmaceuticals to advance NCEL-101 program for type 1 diabetes	RE

31/07	NewcelX Announces Pricing of $1.4 Million Equity Financing at 20% Premium Pricing	AQ
15/07	NewcelX Granted Patent in Brazil for NCEL-101 in Type 1 Diabetes, Expanding Global IP Portfolio	AQ
08/07	NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board	AQ
08/07	The Longevity Protein Race Reaches Manufacturing: One Microcap Just Completed A GMP Master Cell Bank For Its Anti-Aging Klotho Therapy	AQ
01/07	NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes	AQ

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
KADIMASTEM	-0.78%	+153.00%	-	-	1.78Cr
LONZA GROUP AG	+0.99%	+1.78%	+5.07%	+16.49%	4.95TCr
REVOLUTION MEDICINES, INC.	+3.71%	+9.40%	+486.14%	+579.98%	4.4TCr
BEONE MEDICINES AG	+5.60%	+10.21%	+20.85%	+81.78%	3.96TCr
IQVIA HOLDINGS INC.	+2.70%	+1.57%	+32.71%	+9.07%	3.93TCr
CELLTRION, INC.	+2.21%	+6.75%	+20.20%	+54.40%	3.24TCr
ASCENDIS PHARMA A/S	+2.23%	+4.71%	-	-	1.68TCr
MEDPACE HOLDINGS, INC.	+0.97%	+2.35%	+35.99%	+124.45%	1.65TCr
EUROFINS SCIENTIFIC SE	-0.11%	+2.41%	+5.03%	+20.47%	1.4TCr
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+0.75%	+15.04%	+79.84%	+29.70%	1.28TCr
Average	+1.83%	+6.32%	+85.73%	+114.54%	2.94TCr
Weighted average by Cap.	+2.54%	+6.10%	+105.13%	+138.67%

	2026 *	2027 *
Net sales	-	-
Net income	-	-
Net Debt	-	-

Kadimastem Share Price OTC Markets

Stocks

KMSTF

IL0011284614

Biotechnology & Medical Research

Valuation: Kadimastem

Latest news : Kadimastem

Analysts' recommendations: Kadimastem

Press Releases: Kadimastem

Quotes and Performance

Other Biotechnology & Medical Research

Financials

Company Profile